RxDoctor Payments Data

Yuliya Rashevska, APRN

Psychiatric/Mental Health · Willowbrook, ILNPI 1619526175

Payments from drug & device makers

$1,978in general payments, 2019–2025

Across 77 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$412
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$170
  • Novo Nordisk$169
  • Alkermes, Inc.$165
  • Johnson & Johnson$149
  • Otsuka America Pharmaceutical, Inc.$124
  • plus $790 from 17 others

What the payments were for

  • Food & beverage$1,978100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,978 in reported general payments places this provider in the 80th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$5,994
Medicare patients
51
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole15$22,730
Divalproex Sodium55$3,861
Aripiprazole53$3,440
Divalproex Sodium ErDivalproex Sodium83$2,111
Ziprasidone Hcl26$1,902
Clozapine12$836
Olanzapine65$810
Haloperidol23$776
Benztropine Mesylate67$746
Venlafaxine Hcl ErVenlafaxine Hcl36$713
Fluvoxamine Maleate23$612
Sertraline Hcl86$534
Oxcarbazepine14$533
Quetiapine Fumarate29$498
Risperidone67$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$124$22,73015 claims
Almatica Pharma LLCSertraline Hcl$16$53486 claims
Teva Pharmaceuticals USA, Inc.Loxapine$63$48017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Willowbrook

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →